Are Two Immunotherapy Agents Better than One? Will the MYSTIC Trial Prove to Be a Mistake? (BMIC-003)
Aug 29, 2017•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in progression-free survival with an IT combination.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast